Full text is available at the source.
Abstract
An analysis of semaglutide use shows potential cardiovascular benefits for trial participants with frailty.
- Frailty is characterized by accumulated age-related health deficits.
- Semaglutide may be associated with improved cardiovascular outcomes in this population.
- Safety of semaglutide in frail individuals remains a key consideration.
- Further research is needed to confirm these findings and understand the implications.
Simplified